A detailed history of Goldman Sachs Group Inc transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Goldman Sachs Group Inc holds 226,341 shares of IMCR stock, worth $6.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226,341
Previous 90,184 150.98%
Holding current value
$6.41 Million
Previous $3.06 Million 130.53%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.06 - $41.49 $4.09 Million - $5.65 Million
136,157 Added 150.98%
226,341 $7.05 Million
Q2 2024

Aug 13, 2024

SELL
$33.78 - $63.75 $223,724 - $422,216
-6,623 Reduced 6.84%
90,184 $3.06 Million
Q1 2024

May 15, 2024

BUY
$60.14 - $75.36 $2.89 Million - $3.63 Million
48,135 Added 98.9%
96,807 $6.29 Million
Q4 2023

Feb 13, 2024

SELL
$42.85 - $69.5 $1.14 Million - $1.85 Million
-26,633 Reduced 35.37%
48,672 $3.33 Million
Q3 2023

May 14, 2024

BUY
$49.5 - $66.6 $1.32 Million - $1.77 Million
26,633 Added 54.72%
75,305 $3.91 Million
Q3 2023

Nov 14, 2023

SELL
$49.5 - $66.6 $629,689 - $847,218
-12,721 Reduced 14.45%
75,305 $3.91 Million
Q2 2023

May 14, 2024

BUY
$48.54 - $61.64 $2.28 Million - $2.9 Million
47,046 Added 114.8%
88,026 $5.28 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $2.28 Million - $2.9 Million
47,046 Added 114.8%
88,026 $5.28 Million
Q1 2023

May 14, 2024

SELL
$46.12 - $65.71 $108,981 - $155,272
-2,363 Reduced 5.45%
40,980 $2.03 Million
Q1 2023

May 11, 2023

SELL
$46.12 - $65.71 $108,981 - $155,272
-2,363 Reduced 5.45%
40,980 $2.03 Million
Q4 2022

May 14, 2024

SELL
$45.51 - $65.08 $242,522 - $346,811
-5,329 Reduced 10.95%
43,343 $2.47 Million
Q4 2022

Feb 13, 2023

BUY
$45.51 - $65.08 $1.97 Million - $2.82 Million
43,343 New
43,343 $2.47 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.24B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.